Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells

British Journal of Cancer

Volumn 110, Issue 12, 2014, Pages 2865-2873

  Mancini, M ^a   Gariboldi, M B ^a   Taiana, E ^a   Bonzi, M C ^a   Craparotta, I ^a   Pagin, M ^a   Monti, E ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Hypoxia; IGFs; Migration; Triple negative breast cancer

Indexed keywords

ANTIBODIES, MONOCLONAL; CELL HYPOXIA; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MCF-7 CELLS; PYRIMIDINES; PYRROLES; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; TOPOISOMERASE I INHIBITORS; TOPOTECAN; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84902548089     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.269     Document Type: Article

References (40)

1. Alvarez RH, Valero V, Hortobagyi GN (2010) Emerging targeted therapies for breast cancer. J Clin Oncol 28(20): 3366-3379
2. Belfiore A (2007) The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 13(7): 671-686
3. Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, Jassem J, Köstler WJ, Krainer M, Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken N, Wiltschke C, Zielinski CC, Zwierzina H. (CECOG) CECOG (2009) Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 20(11): 1771-1785
4. Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N, Rosenfeld-Franklin M, Lerner L, Chiu MI, Wild R, Epstein D, Pachter JA, Miglarese MR (2010) Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1 R): Rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther 9(10): 2652-2664
5. Davison Z, De Blacquière GE, Westley BR, May FE (2011) Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: Implications for therapy. Neoplasia 13(6): 504-515
6. Feldser D, Agani F, Iyer N, Pak B, Ferreira G, Semenza G (1999) Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 59(16): 3915-3918. (Pubitemid 29393552
7. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A, Vigneri R (1999) Insulin receptor isoform A, a newly recognized, high-Affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19(5): 3278-3288. (Pubitemid 29193789
8. Gao J, Chang YS, Jallal B, Viner J (2012) Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology. Cancer Res 72(1): 3-12
9. Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L, Veldman-Jones M, Blakey DC, Tabrizi M, Jallal B, Trail PA, Coats S, Bosslet K, Chang YS (2011) Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res 71(3): 1029-1040
10. García-Echeverría C, Pearson M, Marti A, Meyer T, Mestan J, Zimmermann J, Gao J, Brueggen J, Capraro H, Cozens R, Evans D, Fabbro D, Furet P, Porta D, Liebetanz J, Martiny-Baron G, Ruetz S, Hofmann F (2004) In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5(3): 231-239
11. Gariboldi M, Ravizza R, Monti E (2010) The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-Angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells. Biochem Pharmacol 80(4): 455-462
12. Guarneri V, Conte P (2009) Metastatic breast cancer: Therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist 14(7): 645-656
13. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351(9113): 1393-1396. (Pubitemid 28209997
14. Helle SI (2004) The insulin-like growth factor system in advanced breast cancer. Best Pract Res Clin Endocrinol Metab 18(1): 67-79
15. Karamouzis MV, Papavassiliou AG (2012) Targeting insulin-like growth factor in breast cancer therapeutics. Crit Rev Oncol Hematol 84(1): 8-17
16. Liedtke C, Kiesel L (2011) Current issues of targeted therapy in metastatic triple-negative breast cancer. Breast Care (Basel) 6(3): 234-239
17. Martin JL, Baxter RC (2011) Signalling pathways of insulin-like growth factors (IGFs) and IGF binding protein-3. Growth Factors 29(6): 235-244
18. McCann AH, Miller N, O'Meara A, Pedersen I, Keogh K, Gorey T, Dervan PA (1996) Biallelic expression of the IGF2 gene in human breast disease. Hum Mol Genet 5(8): 1123-1127. (Pubitemid 26318550
19. Onnis B, Rapisarda A, Melillo G (2009) Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med 13(9A): 2780-2786
20. Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, Fujita-Yamaguchi Y, Siddle K, Goldfine ID, Belfiore A (1999) Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: Evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 5(7): 1935-1944. (Pubitemid 29334478
21. Pollak M (2008a) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8(12): 915-928
22. Pollak M (2008b) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8(12): 915-928
23. Pollak M (2012) The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat Rev Cancer 12(3): 159-169
24. Reis-Filho J, Tutt A (2008) Triple negative tumours: A critical review. Histopathology 52(1): 108-118. (Pubitemid 350265179
25. Richardson AE, Hamilton N, Davis W, Brito C, De León D (2011) Insulin-like growth factor-2 (IGF-2) activates estrogen receptor-A and-b via the IGF-1 and the insulin receptors in breast cancer cells. Growth Factors 29(2-3): 82-93
26. Sachdev D, Yee D (2001) The IGF system and breast cancer. Endocr Relat Cancer 8(3): 197-209. (Pubitemid 32947642
27. Sachdev D, Yee D (2007) Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6(1): 1-12. (Pubitemid 46206663
28. Sachdev D, Zhang X, Matise I, Gaillard-Kelly M, Yee D (2010) The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. Oncogene 29(2): 251-262
29. Saldana SM, Lee HH, Lowery FJ, Khotskaya YB, Xia W, Zhang C, Chang SS, Chou CK, Steeg PS, Yu D, Hung MC (2013) Inhibition of type I insulinlike growth factor receptor signaling attenuates the development of breast cancer brain metastasis. PLoS One 8(9): E73406
30. Semenza GL (2012) Hypoxia-inducible factors: Mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 33(4): 207-214
31. Stoeltzing O, Liu W, Reinmuth N, Fan F, Parikh A, Bucana C, Evans D, Semenza G, Ellis L (2003) Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol 163(3): 1001-1011. (Pubitemid 37040136
32. Sánchez-Muñoz A, Pérez-Ruiz E, Jiménez B, Ribelles N, Márquez A, García-Ríos I, Alba Conejo E (2009) Targeted therapy of metastatic breast cancer. Clin Transl Oncol 11(10): 643-650
33. Thomas R, Kim M (2009) A HIF-1alpha-dependent autocrine feedback loop promotes survival of serum-deprived prostate cancer cells. Prostate 69(3): 263-275
34. Vaupel P, Schlenger K, Knoop C, Höckel M (1991) Oxygenation of human tumors: Evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 51(12): 3316-3322
35. Vleugel MM, Greijer AE, Shvarts A, van Der Groep P, van Berkel M, Aarbodem Y, van Tinteren H, Harris AL, van Diest PJ, van Der Wall E (2005) Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol 58(2): 172-177. (Pubitemid 40193803
36. Xia Y, Choi HK, Lee K (2012) Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem 49: 24-40
37. Zhang H, Fagan DH, Zeng X, Freeman KT, Sachdev D, Yee D (2010) Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene 29(17): 2517-2527
38. Zhang H, Pelzer AM, Kiang DT, Yee D (2007) Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res 67(1): 391-397. (Pubitemid 46142798
39. Zhang Y, Moerkens M, Ramaiahgari S, De Bont H, Price L, Meerman J, van De Water B (2011) Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res 13(3): R52
40. Zhu C, Qi X, Chen Y, Sun B, Dai Y, Gu Y (2011) PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in IGF-1-induced VEGF-C upregulation in breast cancer. J Cancer Res Clin Oncol 137(11): 1587-1594.